![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-to-present-positive-phase-2b-enlighten-trial-data-for-dgm4-biomarker-guided-db104-liafensine-treatment-for-treatment-resistant-depression-at-the-ascp-2024-annual-meeting-302152321.html
https://www.prnewswire.com/news-releases/cirm-awards-11-8-million-grant-for-clinical-trial-in-high-grade-glioma-including-glioblastoma-using-db107--a-novel-dgm7-genetic-biomarker-guided-gene-therapy-302131547.html
https://www.prnewswire.com/news-releases/denovo-biopharma-announces-a-major-breakthrough-in-treatmentresistant-depression-with-precision-medicine-302106575.html
https://www.prnewswire.com/news-releases/denovo-biopharma-creates-innovative-gene-registry-program-to-support-the-first-precision-medicine-for-treatment-resistant-depression-301763716.html
https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-enlighten-biomarkerguided-global-clinical-trial-of-db104-liafensine-for-treatment-resistant-depression-301595206.html
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-fda-approval-of-ind-to-initiate-first-biomarkerguided-global-cns-clinical-trial-for-treatment-resistant-depression-trd-301470941.html
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-breakthrough-discovery-of-a-novel-genetic-biomarker-for-db107-for-a-gene-therapy-based-medicine-301443422.html
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-breakthrough-discovery-of-a-novel-genetic-biomarker-for-db107-for-a-gene-therapy-based-medicine-301443422.html
https://www.benzinga.com/general/biotech/21/12/24594467/aytu-biopharma-partner-denovo-biopharma-reports-received-fda-clearance-orphan-drug-designation-fo
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-partner-aytu-biopharma-receives-fda-clearance-and-orphan-drug-designation-for-enzastaurin-in-vascular-ehlers-danlos-syndrome-301444292.html